Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Neurocrine ( (NBIX) ).
Neurocrine has announced a leadership transition with Sanjay Keswani, M.D. set to succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has served in the role for seven years, will continue with the company as a Strategic Advisor to the CEO until the end of 2025. The transition involves an amended employment agreement for Dr. Roberts, maintaining her salary and bonus eligibility while ensuring her equity awards continue to vest.
The most recent analyst rating on (NBIX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Neurocrine stock, see the NBIX Stock Forecast page.
Spark’s Take on NBIX Stock
According to Spark, TipRanks’ AI Analyst, NBIX is a Outperform.
Neurocrine’s stock score reflects its strong financial performance and promising developments in R&D, tempered by valuation concerns and operational challenges. While the company’s financial stability and growth potential are significant strengths, high P/E ratio and reimbursement challenges pose risks. The technical analysis suggests mixed signals, indicating potential volatility.
To see Spark’s full report on NBIX stock, click here.
More about Neurocrine
Average Trading Volume: 1,529,634
Technical Sentiment Signal: Buy
Current Market Cap: $12.18B
See more data about NBIX stock on TipRanks’ Stock Analysis page.